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ABSTRACT
Organophosphorus (OP) nerve agents are potent toxins that
inhibit cholinesterases and produce a rapid and lethal cholin-
ergic crisis. Development of protein-based therapeutics is be-
ing pursued with the goal of preventing nerve agent toxicity and
protecting against the long-term side effects of these agents.
The drug-metabolizing enzyme human carboxylesterase 1 (hCE1) is
a candidate protein-based therapeutic because of its similarity
in structure and function to the cholinesterase targets of nerve
agent poisoning. However, the ability of wild-type hCE1 to
process the G-type nerve agents sarin and cyclosarin has not
been determined. We report the crystal structure of hCE1 in
complex with the nerve agent cyclosarin. We further use ste-
reoselective nerve agent analogs to establish that hCE1 exhib-
its a 1700- and 2900-fold preference for the PR enantiomers of
analogs of soman and cyclosarin, respectively, and a 5-fold
preference for the PS isomer of a sarin analog. Finally, we
show that for enzyme inhibited by racemic mixtures of bona
fide nerve agents, hCE1 spontaneously reactivates in the
presence of sarin but not soman or cyclosarin. The addition
of the neutral oxime 2,3-butanedione monoxime increases
the rate of reactivation of hCE1 from sarin inhibition by more
than 60-fold but has no effect on reactivation with the other
agents examined. Taken together, these data demonstrate
that hCE1 is only reactivated after inhibition with the more
toxic PS isomer of sarin. These results provide important
insights toward the long-term goal of designing novel forms
of hCE1 to act as protein-based therapeutics for nerve agent
detoxification.
Originally discovered in 1854 as potent pesticides, organ-
ophosphorus (OP) nerve agents are some of the deadliest
chemical compounds ever synthesized by humans (Newmark,
2007). During the Iran-Iraq war, Iranian soldiers were tar-
geted with several chemical weapons, including sulfur mus-
tard and the OP nerve agent sarin (O-isopropyl methylphos-
phonofluoridate). In 1988, Saddam Hussein used sarin and
the related OP agent tabun (ethyl N,N-dimethylphosphor-
amidocyanidate) against Kurdish citizens in Halabja, killing
5000 (Newmark, 2007). More recently, the cult Aum Shin-
rikyo released diluted sarin in the Tokyo subway system in
1995, killing 12 and affecting thousands (Okumura et al.,
2005). Even though these and related compounds were
banned by the 1997 Chemical Weapons Warfare Convention,
their ease of synthesis and known use by rogue nations and
terrorist groups continue to pose a security threat (Trapp,
2006).
OP nerve agents are alkylphosphonic esters (Fig. 1) that
covalently modify a variety of enzymes, most importantly the
neurotransmitter regulating enzyme acetylcholinesterase
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(AChE). AChE inhibition leads to continual acetylcholine
stimulus of the muscarinic and nicotinic receptors, resulting
in seizures, convulsions, diaphragm incapacitation, and, in
cases of higher-dose exposure, death. After phosphonylation
of the catalytic serine in AChE, a spontaneous, time-depen-
dent dealkylation may occur (known as aging), resulting in a
stable phosphonylated enzyme that is resistant to recovery
therapies (Jokanovic, 2009). The PS enantiomers of sarin,
soman (O-pinacolyl methylphosphonofluoridate), and cyclo-
sarin (O-cyclohexyl methylphosphonofluoridate) are signifi-
cantly more lethal than the PR isomers because of their
preferential inhibition of the AChE enzyme (Kovarik et al.,
2003).
Current treatments for nerve agent poisoning include in-
jections of atropine, a competitive inhibitor of acetylcholine
at the muscarinic receptor, to turn off muscle stimulus, and
a strong nucleophilic oxime such as pralidoxime chloride, to
dephosphonylate the AChE catalytic serine before aging
(Gray, 1984). Both of the compounds offer limited protection
because they cannot be administered before exposure and do
not address any of the long-term side effects associated with
nerve agent poisoning (Doctor and Saxena, 2005). Prophylac-
tic protein-based therapeutics are emerging as a means to
protect against both toxicity and long-term side effects in
nerve agent poisoning (Lenz et al., 2007). These biological
reagents act as “bioscavengers” to stoichiometrically seques-
ter nerve agents before AChE inhibition (Dunn and Sidell,
1989). Preadministration of excess bioscavenger in mice pro-
vides protection against mortality equivalent to a postexpo-
sure oxime injection but is superior at minimizing postexpo-
sure effects such as lacrimation or decreased motor function
(Maxwell et al., 1993; Doctor and Saxena, 2005). Current
stoichiometric bioscavengers include AChE and the related
serine hydrolase butyrylcholinesterase (BuChE). A more ad-
vanced protein-based therapeutic would include a catalytic
function to detoxify nerve agents before AChE inhibition
reaches lethal levels. For example, human serum paraoxo-
nase and bacterial organophosphorus hydrolase are being
studied for this application (Lenz et al., 2007; Reeves et al.,
2008).
Human carboxylesterase 1 (hCE1) is a 62-kDa serine hy-
drolase belonging to the same / hydrolase superfamily as
AChE and BuChE but may offer some benefits over cholines-
terases as a potential catalytic nerve agent, hydrolase. In-
deed, high-serum carboxylesterase concentrations in rodents
and mosquitoes protect these species from OP nerve agent
exposure (Maxwell, 1992; Heidari et al., 2004). hCE1, found
primarily in the liver, uses a catalytic triad composed of a
serine, histidine, and glutamic acid in a standard two-step
serine hydrolase catalytic mechanism. hCE1 cleaves ester,
thioester, and amine-ester bonds in a variety of endogenous
and xenobiotic compounds (Redinbo and Potter, 2005). We
published previously the crystal structures of hCE1 in cova-
lent acyl-enzyme complexes with the nerve agents soman and
tabun (Fleming et al., 2007). However, the ability of hCE1 to
reverse covalent inhibition and reactivate wild-type activity
was not examined in that study.
Here we present a 3.1-Å X-ray nonaged crystal structure of
hCE1 in covalent complex with the nerve agent cyclosarin,
the first structure determined of any protein bound to this
agent. To further examine the potential of hCE1 as either a
bioscavenger or a nerve agent hydrolase, we used bona fide
nerve agents and stereogenic analogs thereof to measure the
bimolecular rates of inhibition and the spontaneous and
oxime-assisted rates of reactivation of hCE1 in the presence
of sarin, soman, and cyclosarin. Last, we examine the pro-
pensity of hCE1 to age in the presence of nerve agent ad-
ducts. These crystallographic and biochemical data advance
our understanding of the ability of hCE1 to process organo-
phosphorus compounds and will assist in the potential devel-
Fig. 1. Organophosphate nerve agents and nerve agent
analogs. Nerve agents contain a methyl, O-alkoxy, and
good leaving group built on a central chiral phosphonate.
The stereogenic OP nerve agent analogs contain a thio-
methyl leaving group in place of the fluoride.
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opment of this enzyme as a protein-based therapeutic to
prevent nerve agent toxicity.
Materials and Methods
Nerve Agent Inhibition and Crystallization. hCE1 was ex-
pressed and secreted from baculovirus-infected Spodoptera frugi-
perda Sf21 cells and purified to 98% homogeneity by SDS-poly-
acrylamide gel electrophoresis as described previously (Morton and
Potter, 2000). At the United States Army Medical Research Institute
of Chemical Defense (Aberdeen Proving Ground, MD), 2 mg of puri-
fied protein was incubated with 10-fold molar excess of racemic
cyclosarin (obtained from the Research Development and Engineer-
ing Command, Aberdeen Proving Ground, MD) for 1 h at room
temperature. Excess unbound agent was removed by passing inhib-
ited hCE1 over a PD-10 Sephadex G-25 size exclusion chromatogra-
phy column (GE Healthcare, Chalfont St. Giles, Buckinghamshire,
UK). Postcolumn samples were tested to confirm complete inhibition
by measuring hydrolysis of para-nitrophenyl butyrate (pNPB;
Sigma-Aldrich, St. Louis, MO), a conventional esterase substrate
(Wierdl et al., 2008). To assess the extent to which excess cyclosarin
was retained within the column, the capacity of the eluate to subse-
quently inhibit BuChE was also determined. Cyclosarin-inhibited
hCE1 was concentrated to 3 mg/ml using Amicon Ultra-15 (Milli-
pore, Billerica, MA) spin concentrators. Plate-like crystals (600 
100  50 M) were grown in 4 to 6 weeks using the sitting drop
vapor-diffusion method in 10% polyethylene glycol 3350, 0.3 M
Li2SO4, 0.1 M citrate, pH 5.5, 0.1 M NaCl, 0.1 M LiCl, and 5%
glycerol. Before cooling to 100 K in liquid nitrogen, crystals were
cryoprotected by stepwise passages into a final concentration of 30%
(w/v) sucrose plus mother liquor.
Structure Determination and Refinement. X-Ray diffraction
data were collected at 100 K at the Advanced Photon Source at
Argonne National Laboratory (Argonne, IL) on beam line 22-ID
(Southeast Regional Collaborative Access Team, Argonne National
Laboratory). Data were indexed and scaled using the XDS package
(Kabsch, 1988). Molecular replacement was conducted using MolRep
in the CCP4i suite (Collaborative Computational Project, 1994) (ver-
sion 6.1.0) with one trimer of the hCE1-tacrine structure (RCSB PDB
access code 1mx1; Bencharit et al., 2003) as the search model. The
hCE1-cyclosarin model was refined using rigid body, simulated an-
nealing, and grouped B-factor refinements in the Crystallography
and NMR System (Brünger et al., 1998) that included an overall
anisotropic B-factor, bulk solvent correction, and noncrystallo-
graphic symmetry restraints for regions outside the active site. Be-
fore any structural refinement, a subset (7%) of the data was set
aside for cross-validation by Rfree calculation. Manual building was
conducted in Coot (Emsley and Cowtan, 2004) with a-weighted
composite omit, difference density, and simulated annealing omit
maps. Data collection and refinement statistics were summarized
and are presented in Table 1. The final structure was validated using
PROCHECK (Laskowski et al., 1993), and all figures were generated
in PyMol (DeLano Scientific, Palo Alto, CA). Coordinates and struc-
ture factors were deposited at the PDB with access code 3k9b.
Inhibition Rate Constants Using Nerve Agent Analogs.
Samples of purified hCE1 at 100 nM were inhibited at room temper-
ature with increasing concentrations of stereogenic OP nerve agent
analogs. Aliquots of enzyme incubated with stereoisomer analogs of
sarin (PR, PS), PS soman, and PS cyclosarin were removed at various
time points (up to 1 h), and the level of active enzyme that remained
was determined by comparing pNPB hydrolysis relative to an unin-
hibited sample. Because the PR soman and PR cyclosarin analogs
react more quickly with hCE1, the affects these analogs had on hCE1
were measured continuously (for up to 15 min) by adding increasing
concentrations of analog to hCE1 samples containing pNPB and by
measuring the loss of functional enzyme activity over time. These
data, collected at 410 nm and 25°C on a Pherastar microplate reader
(BMG Labtech, Durham, NC), were corrected for spontaneous pNPB











where Kd is the dissociation constant, k2 is the unimolecular phos-
phorylation rate constant, v is the remaining percentage of enzyme
activity, [IX] is the OP analog concentration,  is [S]/(KM 	 [S]), in
which [S] is the substrate concentration and KM is the Michaelis-
Menten constant. All experiments were performed in triplicate. Data
were analyzed using KaleidaGraph 4 (Synergy Software, Reading,
PA) to determine ki (ki 
 k2/Kd) values.
Spontaneous Reactivation. Fifty microliters of COS cell lysate
expressing a nonsecreted form of hCE1, prepared as described pre-
viously (Wierdl et al., 2008), was inhibited with a 1000-fold molar
excess of racemic OP agents sarin, soman, or cyclosarin for 10 min.
Excess agent was removed by passing inhibited samples over a
PD-10 Sephadex G-25 exclusion column (GE Healthcare). The col-
umn eluate was diluted 10-fold in 0.1 M potassium phosphate buffer,
pH 7.4, and tested for the presence or absence of carboxylesterase
activity and complete removal of excess agent, as described previ-
ously. Aliquots were removed over time (up to 80 h), and the per-
centage of enzyme activity was measured by pNPB hydrolysis rela-
tive to an uninhibited sample. The rate of reactivation (kobs) and
maximal percentage of recovery (Amax) were determined by fitting
the data to eq. 2:
A  A0  Amax1  ekobst (2)
where A is the percentage of activity at time t, and A0 is the initial
activity at t 
 0. The experiments were conducted in triplicate, and
data were analyzed using Sigma Plot version 8.02 (Systat Software
Inc., San Jose, CA).
Oxime-Assisted Reactivation. Fifty microliters of COS cell ly-
sate containing hCE1 was inhibited, and excess agent was removed
as described previously. Stereogenic OP analogs were used in a
fashion similar to that of racemic nerve agents but required a longer
incubation time (up to 1 h). Upon column elution, samples were
diluted 10-fold into 1 mM 2,3-butanedione monoxime (DAM; Sigma-
Aldrich), which had been prepared previously in 0.1 M potassium
TABLE 1





a, b, c (Å) 55.6, 179.9, 200.6
, , 	 (°) 90.0, 90.0, 90.0




Completeness (%) 97.5 (94.0)
Redundancy 7.0 (6.2)
Crystallographic refinement
Resolution (Å) 48–3.1 (3.3–3.1)
Unique reflections 36,488




Bond lengths (Å) 0.014
Bond angles (°) 1.70
Rwork/Rfree (%)
c,d 26.6 (26.8)/29.9 (29.6)
a Number in parentheses is for the highest shell.
b Rsym 
 I  I I, where I is the observed intensity and I is the average
intensity of multiple symmetry-related observations of that reflection.
c Rwork 
  Fo  Fc/Fo, where Fo and Fc are the observed and calculated
structure factors, respectively.
d Rfree 
  Fo  Fc/Fo for 7% of the data not used at any stage of structural
refinement.
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phosphate, pH 7.4, and kept on ice. DAM had no inhibitory effect on
hCE1 at this concentration (data not shown). Aliquots were removed
over time, and enzyme activity was measured as described above.
The rate of reactivation (kobs) and maximal percentage of reactiva-
tion (Amax) were determined for each agent/analog by subtracting
background oxime-induced pNPB hydrolysis and fitting the data to
eq. 2.
Aging. Samples of 1 M purified hCE1 were inhibited with a
1000-fold molar excess of the PS sarin, soman, and cyclosarin analogs
for 60 min at room temperature. Complete inhibition was verified by
the absence of pNPB hydrolysis. Excess unbound agent was removed
by size-exclusion chromatography as described previously, and ali-
quots were diluted 1:10 into 1 mM DAM every 12 h for 48 h. After
dilution into DAM, each sample was incubated for 24 h to achieve
maximal DAM-assisted reactivation, and then enzyme activity was
measured and the percentage of reactivation was determined rela-
tive to an uninhibited sample. Maximum percentage of reactivation
(Amax) was plotted against the incubation time in the absence of
DAM and fitted to eq. 3 (Shafferman et al., 1996):
Amax  Amax0expkat (3)
where Amax0 was the maximum recovery at time 
 0, and ka was the
rate of aging.
Results
Crystal Structure of the hCE1-Cyclosarin Complex.
The crystal structure of hCE1 in a covalent acyl-enzyme
intermediate complex with the OP nerve agent cyclosarin
was determined by molecular replacement and refined to 3.1
Å resolution (Table 1). The hCE1-cyclosarin structure was
similar to ligand complexes of this enzyme described previ-
ously, with a root mean square deviation (RMSD) of 0.48 Å
over 1354 equivalent C positions compared with the hCE1-
tacrine structure (Bencharit et al., 2003). The initial maps
were of good quality for the majority of the polypeptide, with
the exception of the acyl loop (residues 304–318) that caps
the active site and five short loops (340–342, 369–374, 406–
410, 450–454, 483–488) between secondary structural ele-
ments. When positioned provisionally, these disordered re-
gions displayed B-factors of 90 Å2; in contrast, the average
B-factor of the ordered regions of the final model was 54 Å2.
Two of these regions (369–374, 450–454) were also disor-
dered in the structure of a rabbit liver carboxylesterase,
which shares 81% sequence identity and 0.42 Å RMSD over
401 equivalent C positions relative to hCE1 (Bencharit et
al., 2002). The model of hCE1 complexed with cyclosarin was
refined to final R factors of 26.6% (Rcryst) and 29.9% (Rfree)
(Table 1).
Each hCE1 monomer, supported by two disulfide links
(Cys87–Cys116, Cys274–Cys285), contained two ligand bind-
ing sites within three domains: catalytic, /, and regulatory
(Bencharit et al., 2002) (Fig. 2). The hCE1-trimer was formed
through C3 symmetry around respective / domains and
buries 475 Å2 of solvent-accessible surface area per protein
monomer. The primary ligand binding site, the active site,
was located at the interface of the three domains in each
monomer and was composed of the Ser221, His468, and
Glu354 catalytic triad. The second ligand binding site (or
Z-site) was on the enzyme’s surface at the interface between
the regulatory and catalytic domains. Previous crystal struc-
tures of hCE1 in complex with OP nerve agents soman and
tabun contained sucrose, the cryoprotectant, in the Z-site
(Fleming et al., 2007). Ser369, which forms a hydrogen bond
with the O1 of sucrose in these other structures, was disor-
dered in the hCE1-cyclosarin structure, and no ligand mole-
cule was observed in this site. The catalytic domain also
contained a high-mannose glycosylation site at Asn79. Den-
sity was observed around Asn79, but neither N-acetylglu-
cosamine nor terminal sialic acid could be reliably built and
refined into this region.
OP nerve agents inhibit hCE1 by forming a covalent ad-
duct with the catalytic serine (Fig. 3A). In the structure of the
hCE1-cyclosarin complex reported here, a covalent cyclosarin
adduct was easily identified in initial difference density (F0 
Fc) maps as a 6  electron density peak approximately 1.6 Å
away from the Ser 221 O	, which corresponded to the nerve
agent phosphate. At lower  levels (2.5–4 ), additional den-
sity for the complete molecule was apparent. The cyclosarin
model was built into the observed density, refined, and PR
stereochemistry was assigned around the chiral phosphate
(Fig. 3B). The acyl-enzyme adduct was stabilized by two
hydrogen bonds. These occur between the cyclosarin phos-
phoryl oxygen atom and hydrogen atoms present on the
amide nitrogens within residues Gly142 and Gly143 (2.6 and
2.4 Å, respectively). The O-cyclohexyl alkoxy group is located
within the larger, flexible pocket of the active site and is
stabilized by interactions with Leu363 of the regulatory do-
main. The stereochemistry and alkoxy placement was con-
firmed with a 3.1-Å resolution simulated annealing omit
map, contoured to 5  (Fig. 4A). The opposite PS isomer was
also built into the starting model, and one round of refine-
ment was performed. Clear positive and negative density from
a difference density map (F0  Fc, 
Calc) verified the PR as-
signment as consistent with the biochemical results (Fig. 4B).
Nerve Agent Analog Stereopreference of hCE1. Sa-
rin, soman, and cyclosarin contain a chiral phosphorus atom
and exist as racemic mixtures of PR and PS stereoisomers.
Soman also has an asymmetric carbon (C) in the pinacolyl
group. The PS isomers of sarin, soman, and cyclosarin inhibit
AChE more potently than the PR forms; for example, the
preference of PS versus PR soman is 5000-fold for AChE
(Sanson et al., 2009). Using OP nerve agent analogs contain-
ing a thiomethyl-leaving group prepared as purified stereo-
Fig. 2. hCE1 monomer. Each protein monomer has three domains; the
/ domain (blue) forms the trimer interface and caps the active site; the
regulatory region (orange) contains the secondary surface binding site
(Z-site) and Glu354 of the catalytic triad; and the catalytic domain (green)
contains the central -sheet conserved in serine hydrolases and the two
catalytic residues His468 and Ser221. There are two disulfide bonds
(cyan), one in the / domain and the other in the catalytic domain, and
one glycosylation site, at Asn79 (yellow).
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isomers (Fig. 1), we determined the stereoselectivity of hCE1
inhibition by analogs of sarin, soman, and cyclosarin (Fig. 5).
These analogs have been shown by matrix-assisted laser
desorption ionization/time of flight mass spectrometry to
yield, among other products, acyl-enzyme adducts identical
with those from authentic agents when used to inhibit bu-
tyrylcholinesterase (Gilley et al., 2009). The thiomethyl-leav-
ing group that replaces the fluoride atom found in nerve agents
decreases the toxicity of the analogs by slowing the rate of
phosphonylation (k2) compared with real agents; however, the
dissociation constants (Kd) remain similar (Forsberg and Puu,
1984). The decrease in k2 results in a reduction in the bimolec-
ular rate of inhibition (ki) by 2 to 3 orders of magnitude com-
pared with the corresponding nerve agent (Maxwell, 1992). PR
analogs of soman and cyclosarin inhibited hCE1 1700- and
2900-fold more efficiently than the PS isomers, respectively
(Fig. 5). In contrast, hCE1 exhibited a 5-fold preference for the
PS versus PR form of the sarin analogs (Fig. 5). As discussed
below, this may be because the smaller O-isopropyl group in the
sarin analogs is more easily accommodated in the hCE1 active
site than that larger O-pinacolyl and O-cyclohexyl groups of the
soman and cyclosarin analogs, respectively. Taken together,
these results demonstrate that hCE1 exhibits a strong prefer-
ence for the PR soman and cyclosarin analogs and a smaller
preference for the PS isomer of the smaller sarin analog.
Spontaneous Reactivation of hCE1. After the formation
of the acyl-enzyme intermediate, proteins exposed to OP nerve
agents may remain stably adducted, permanently inhibited
(aged), or undergo spontaneous hydrolysis (hereafter referred to
as reactivation) reversing the phosphonylation and returning
the enzyme to normal function (Langenberg et al., 1988; Li et
al., 2007). To test the ability of hCE1 to reactivate after inhibi-
tion by nerve agents, the enzyme was challenged with racemic
mixtures of the OP nerve agents soman, sarin, and cyclosarin.
We found that only samples inhibited with sarin exhibited
spontaneous reactivation (Fig. 6A), with a half-time of 45 h
(kobs 
 2.58  0.06  10
4/min). When carried out to 300 h,
a maximum activity of 84  6% was recovered (data not
shown). The rate of reactivation was approximately 10-fold
slower than that measured for rat serum carboxylesterase
(Maxwell and Brecht, 2001) but 10-fold faster than BuChE
(Bartling et al., 2007). In contrast, AChE exhibits no reacti-
vation after sarin inhibition (Bartling et al., 2007). hCE1
inhibited with soman and cyclosarin, however, exhibited poor
reactivation and achieved a maximum recovery of activity of
only 10% even after 300 h (Fig. 6A). These data establish
that reactivation of hCE1 only occurs after exposure to sarin.
Oxime-Assisted Reactivation of hCE1. Strong oxime
nucleophiles like pralidoxime chloride and obidoxime are
known to reactivate OP-inhibited esterases, particularly AChE,
by promoting the dephosphonylation of the active site serine.
These cationic oximes are currently used as part of postexpo-
sure therapy and are appropriate for the anionic choline bind-
ing gorge in cholinesterases (Volans, 1996). Carboxylesterases
such as hCE1 react poorly with charged substrates (Maxwell et
al., 1994); however, the ability of a neutral oxime like DAM to
reactivate inhibited hCE1 has not been reported in the litera-
ture. Thus, we tested whether DAM would reactivate hCE1
that had been exposed to racemic mixtures of OP nerve agents.
We found that DAM enhanced the reactivation of sarin-inhib-
Fig. 3. hCE1-cyclosarin complex. A, chemi-
cal scheme of hCE1 reacting with cyclosa-
rin. B, cut-away view of the hCE1-cyclo-
sarin active site. The catalytic triad and
cyclosarin molecule are shown in purple,
oxyanion hole in white, and the surround-
ing residues in green. Hydrogen bonds be-
tween the phosphoryl oxygen and the
backbone nitrogen atoms in the oxyanion
hole are shown in red.
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ited hCE1 but not enzyme inhibited by soman or cyclosarin
(Fig. 6B). In the presence of DAM, sarin-inhibited hCE1 exhib-
ited a half-time of reactivation of 41 min (kobs 
 0.0168 
0.0003 min1 mM1), approximately 66-fold faster than that
observed without the oxime (see Fig. 6A). In addition, similar to
spontaneous reactivation, the maximal recovery of hCE1 that
was observed in the presence of DAM was 89  4%. Thus, the
neutral oxime DAM increased the rate of reactivation of sarin-
inhibited hCE1 by more than 65-fold.
We next examined the ability of DAM to enhance the
reactivation of hCE1 inhibited with pure enantiomeric PR or
PS isoforms of the nerve agent analogs (see Fig. 1). We found
that hCE1 inhibited with the PS sarin analog exhibited re-
activation with a half-time of 30 min (kobs 
 0.023  0.004
min1 mM1), whereas hCE1 inhibited by the PR sarin an-
alog exhibited no detectable reactivation (Fig. 6C). In con-
trast, hCE1 samples inhibited with PS soman and cyclosarin
analogs were capable of marginal reactivation, whereas re-
spective PR analogs displayed no recovery (Fig. 6, D and E).
Taken together, these data suggest that the reactivation of
hCE1 in the presence of the sarin analog was due to the
hydrolysis of the PS isomer, whereas the PR isomer cannot be
removed from the active site even in the presence of DAM.
Aging in OP-Inhibited hCE1. Aging in serine hydrolases
involves the time-dependent dealkylation of the bound adduct,
resulting in a permanently phosphorylated catalytic serine res-
idue (Li et al., 2007). This process is rapid for soman in the
active site of AChE (t1/2 of 2 min) and is the primary cause of
the toxicity of this agent (Sanson et al., 2009). Once aging has
occurred, nerve agent adducts are inert, even to strong oximes.
We explored the propensity of hCE1 to age in the presence of
nerve agent analog PS stereoisomers by measuring the loss in
the maximal level of DAM-mediated reactivation (Amax) over
time. If the nerve agent analog adduct undergoes time-depen-
dent dealkylation, one would expect an exponential decay for
Amax (Shafferman et al., 1996). Over 48 h, no change in Amax
was observed for any of the agent analogs (Fig. 6F). For exam-
ple, after 2-h exposure of hCE1 to the PS sarin analog, DAM
was capable of reactivating 60% of the enzyme activity (see
Fig. 6B); however, even after 46 additional hours of incubation
with this sarin analog, the same fraction of enzyme activity,
recovered by DAM, was observed (see Fig. 6F). Thus, sarin-
inhibited hCE1 does not seem to undergo the same first-order
aging process that has been observed with other serine hydro-
lases, such as AChE.
Discussion
Organophosphorus nerve agents inactivate the neurotrans-
mitter-regulating enzyme acetylcholinesterase and bind to
other physiologically important proteins, such as albumin,
Fig. 4. hCE1-cyclosarin adduct stereochemistry. Ser221 and His468 of
the catalytic triad and the cyclosarin adduct are shown in purple. The
oxyanion hole is colored white. A, stereoview of a 3.1-Å resolution Fo  Fc
simulated annealing omit map (blue, contoured to 5 ) calculated for the
PR-cyclosarin adduct. B, stereoview of initial difference density maps for
the incorrect PS-cyclosarin adduct (green for positive, shown at 3 ; red
for negative, shown at 3 ).
Fig. 5. Bimolecular rates of inhibition (ki) for hCE1 and
nerve agent analogs. Plotted as log ki, hCE1 exhibits strong
enantiomeric PR preference for soman and cyclosarin ana-
logs, with only slight PS sarin analog selectivity. Dissocia-
tion constants (Kd) are similar to authentic nerve agents,
whereas phosphorylation rates (k2) are 2 to 3 orders of
magnitude slower. (n 
 3, S.E.)
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lipases, and carboxylesterases (Fleming et al., 2007; Li et al.,
2008). As such, these toxins are among the deadliest com-
pounds developed by humans. The U.S. military has pursued
the development of enzyme therapies capable of protecting
personnel from nerve agent exposure (Lenz et al., 2007). In
this report, we present X-ray crystallographic and biochem-
ical data designed to evaluate the ability of hCE1 to act as
potential enzyme-based therapeutic for nerve agent detoxifi-
cation. Although we have previously determined crystal
structures of hCE1 in complexes with soman and tabun
(Fleming et al., 2007), here we report the novel crystal struc-
ture of hCE1 inhibited by cyclosarin (Fig. 2), one of the most
potent inhibitors of human AChE (Gray and Dawson, 1987).
Difference density and simulated annealing omit maps facil-
itated the placement of a covalent adduct with PR stereo-
chemistry bound to the catalytic Ser221 of hCE1 (Fig. 3A).
After covalent adduction of OP nerve agents and analogs to
the catalytic serine, stereochemistry at the phosphorus atom
remains the same. A rearrangement in priority assignment
after collapse of the pentahedral intermediate causes the
covalent phosphonyl-enzyme intermediate to retain the orig-
inal stereochemistry of the OP compound before enzyme
binding (Epstein et al., 2009). Therefore, the PR stereochem-
istry observed in the crystal structure of the hCE1-cyclosarin acyl-
enzyme adduct (see Figs. 3 and 4) corresponds to the preferential
reaction of hCE1 with the PR analog of cyclosarin.
Indeed, using thiomethyl-substituted nerve agent analogs,
we were able to complete experiments designed to examine
the stereoselectivity of hCE1 for these analogs of sarin, so-
man, and cyclosarin (Fig. 4). We found that hCE1 preferen-
tially binds to the PR isomers of cyclosarin and soman ana-
logs, which is opposite to the stereopreference observed for
AChE with bona fide nerve agents. A structural comparison
of the hCE1-soman and hCE1-cyclosarin crystal structures
with AChE-soman (RCSB PDB access code 2wgo; Sanson et
al., 2009) reveals that the bulky PR O-alkoxy group is posi-
tioned into the larger hydrophobic binding pocket of hCE1. In
contrast, this region is occupied in AChE by a long acyl loop
that dips into the active site pocket and precludes binding of
PR nerve agents (Fleming et al., 2007; Sanson et al., 2009).
Therefore, the geometry of the hCE1 active site size dictates
the enantiomeric binding of the bulkier nerve agents soman
and cyclosarin. With the smaller nerve agent sarin, hCE1
demonstrated only a 5-fold preference for the PS isomer of the
sarin nerve agent analog (Fig. 5). Our structures indicate
that although both isomers of sarin will fit in the active site
of the enzyme, only PS sarin is capable of forming stabilizing
hydrophobic contacts with Phe101 and Leu97; PR sarin
Fig. 6. hCE1 reactivation after inhibition by racemic bona fide OP nerve agents or stereospecific nerve agent analogs. A, spontaneous reactivation of racemic
bona fide OP agents. Reactivation only occurs with sarin (f), with a half-time of reactivation of 45 h (n 
 5, S.D.). Soman (F) and cyclosarin () remained
permanently inhibited. B, DAM-assisted reactivation with racemic bona fide nerve agents. Reactivation is only measured against sarin (f) with a
half-time of reactivation of 41 min (n 
 3, S.E.). Soman (F) and cyclosarin () did not reactivate. C, DAM-assisted reactivation of sarin analogs. The
PS isomer (f) reactivates with a half-time of 30 min (n 
 3, S.E.). PR sarin () analog did not reactivate. D, DAM-assisted reactivation of soman
analogs. The greatest reactivation was measured in the PS (E) enantiomer, whereas the PR (F) analog remained inhibited. E, DAM, assisted
reactivation of cyclosarin analogs. Negligible reactivation was measured for either PS () or PR () cyclosarin analog. F, determination of aging with
PS nerve agent analogs; no aging was measured for the PS species.
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would not form analogous interactions (Fig. 7A). These struc-
tural considerations, in part, explain the observed strong
preference for PR soman and cyclosarin and the relatively
weak preference for PS sarin exhibited by hCE1.
After the formation of the acyl-enzyme intermediate, the
first step of the serine hydrolase catalytic mechanism (see
Fig. 3A), nerve agent-esterase complexes can undergo reac-
tivation or aging. Both spontaneous and oxime-assisted re-
activation displaces the acyl-enzyme intermediate and re-
stores the enzyme to normal function. We found that nerve
agent-inhibited hCE1 only reactivates spontaneously, or
with the oxime DAM, after incubation with sarin (Fig. 6, A
and B). In addition, although DAM enhanced the rate of
reactivation 66-fold, both spontaneous and oxime-assisted
reactivation only restores 85% of the original enzyme ac-
tivity. Using the stereogenic nerve agent analogs, we showed
that the rate of DAM-assisted reactivation after inhibition with
the PS sarin analog was identical, within error, with the rate of
DAM-assisted reactivation for racemic sarin (Fig. 6, B and C).
No recovery was measured for the PR sarin analog (Fig. 6C). In
contrast to sarin, hCE1 incubated with racemic samples of the
nerve agents soman or cyclosarin exhibited relatively little re-
activation (Fig. 6, A and B). Furthermore, only weak reactiva-
tion was only achieved with the PS isomers when analogs of
these nerve agents were incubated with hCE1 (Fig. 6, D and E).
Based on these data, we conclude that hCE1 stereoselectively
reactivates PS sarin after racemic inhibition.
We next modeled how hCE1 might preferentially reacti-
vate in the presence of PS sarin (Fig. 7B). Previous work
investigating the influence of pH on spontaneous reactiva-
tion in AChE identified the importance of two ionizable res-
idues with pKa values of 6.9 and 9.8, suggesting possible
histidine and tyrosine residues, respectively (Reiner and Al-
dridge, 1967). In the hCE1 active site, the catalytic His468
neighbors PS sarin and Tyr152 are located approximately 8 Å
away. These two residues are connected via a hydrogen-bonding
network through Glu200 (Fig. 7B). It has been observed in the
structure of the AChE covalent complex with nonaged PS O-
ethyl S-(2-diisopropylaminoethyl) methylphosphonothioate that
the protonated N2 of His440 (His468 in hCE1) rotates away
from Ser200 (Ser221 in hCE1) to form a hydrogen-bond with
Glu199 (Glu220 in hCE1) (Millard et al., 1999). The N2
movement would be expected to be blocked in hCE1 by larger
alkoxy groups, such as the O-pinacolyl group in soman, and is
not observed in the nonaged AChE soman structure (Sanson
et al., 2009). If this shift occurs in hCE1 with PS sarin,
however, the His468 N2 rotation to Glu220 would reorient
the remaining His468 nitrogen, N1, formerly hydrogen-
bonded to Glu354. It would then be positioned to interact
with the PS sarin O2 atom and may act as a general base for
hydrolytic dephosphonylation (Fig. 7B). An analogous orien-
tation of the O2 atom of PR sarin would not be possible while
still maintaining interactions with the oxyanion hole (see
Fig. 7A). By this model, hCE1 will only reactivate after inhi-
bition with PS sarin, consistent with the experimental results
presented above. However, the rate of reactivation is observed
to be poor, probably because of the weak nucleophilicity of
Tyr152 at pH 7.4.
Organophosphinate-esterase complexes may also undergo
aging. Although PS isomers of OPs showed some capability to
be removed from the hCE1 active site by reactivation (Fig. 6,
C–E), we saw no evidence for first-order aging in hCE1 (Fig.
6F). We therefore considered what the fate of the PR-hCE1
adducts is if they do not age and the state of the remaining
percentage of PS-hCE1 adducts that do not undergo reacti-
vation. For complexes of PR organophosphates and hCE1, we
propose that they remain at the acyl-enzyme intermediate
stage of the enzyme’s reaction mechanism. This state has
been observed in the hCE1-PR soman and hCE1-PR cyclo-
sarin crystal structures and via matrix-assisted laser de-
sorption ionization/time of flight analysis of BuChE inhib-
ited by PR analogs of sarin, soman, and cyclosarin (Gilley
et al., 2009). For the 40% of PS-sarin analog complexes
with hCE1 that do not undergo reactivation, we propose
that an alternate Ser221 state is created. In addition to
forming adducts identical with authentic agents, the thio-
methyl-nerve agent analogs used in this study have been
shown to undergo a unique reaction, in which the O-alkoxy
rather than the thiomethyl group is displaced upon col-
lapse of the original pentahedral intermediate (Gilley et
al., 2009). Therefore, dehydroalanine formation at the cat-
alytic serine might also occur with these nerve agent an-
alogs. Mass spectrometry studies were attempted to con-
firm or deny the presence of this adduct in hCE1;
unfortunately, the peptide fragment containing Ser221
could not be isolated, and no useful data were obtained (O.
Lockridge, personal communication).
In summary, these studies establish the stereopreference
of wild-type hCE1 for nerve agent analogs of cyclosarin,
soman, and sarin and confirm this preference for cyclosarin
with crystallographic data. In addition, they indicate that the
native form of hCE1 is capable of reactivation after incuba-
tion with the nerve agent sarin and that the rate of reacti-
vation is enhanced with the neutral oxime DAM. In future
studies, we will use these data to design mutant forms of
Fig. 7. hCE1-sarin model. A, PR and PS enantiomers of
sarin modeled in the hCE1 active site. The O-isopropyl
group on PS sarin makes hydrophobic contacts with Phe101
and Leu97, whereas PR does not have any additional inter-
actions. B, model of proposed mechanism of PS sarin reac-
tivation in hCE1. In AChE, His468 has been observed to
rotate away from Glu354 and interact with Glu221 after
acylation. Modeling this shift in the hCE1 active site, there
is an electronic network formed between Tyr152 (green)
and His468 (yellow) that may either deprotonate N2 or
allow N1 of His468 to act as a general base for water
activation. PS sarin (blue) was modeled into the hCE1-
soman structure (RCSB PDB access code 2hrq; Fleming
et al., 2007).
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hCE1 with the goal of enhancing nerve agent hydrolysis not
only for sarin but also for soman and cyclosarin.
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